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Idiopathic inflammatory myopathies represent still a diagnostic and therapeutic challenge
in different disciplines including neurology, rheumatology, and dermatology. In recent
years, the spectrum of idiopathic inflammatory myopathies has been significantly
extended and the different manifestations were described in more detail leading
to new classification criteria. A major breakthrough has also occurred with respect
to new biomarkers especially with the characterization of new autoantibody-antigen
systems, which can be separated in myositis specific antibodies and myositis associated
antibodies. These markers are detectable in approximately 80% of patients and
facilitate not only the diagnostic procedures, but provide also important information on
stratification of patients with respect to organ involvement, risk of cancer and overall
prognosis of disease. Therefore, it is not only of importance to know the significance of
these markers and to be familiar with the optimal diagnostic tests, but also with potential
limitations in detection. This article focuses mainly on antibodies which are specific
for myositis providing an overview on the targeted antigens, the available detection
procedures and clinical association. As major tasks for the near future, the need of
an international standardization is discussed for detection methods of autoantibodies in
idiopathic inflammatory myopathies. Furthermore, additional investigations are required
to improve stratification of patients with idiopathic inflammatory myopathies according
to their antibody profile with respect to response to different treatment options.
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INTRODUCTION
Idiopathic inflammatory myopathies (IIM) represent a heterogeneous group of acquired muscle
diseases with so far unclear etiology. The different entities are associated with diverse clinical
symptoms ranging from amyopathic to necrotic inflammatory muscle involvement, typical skin
and internal organ involvement. In addition to the clinical picture, histological and serological
findings are especially supportive in differentiation and stratification of disease (1). Based on
this characteristics, IIM can be classified into different major sub-types: (i) polymyositis (PM),
(ii) sporadic inclusion body myositis (sIBM), (iii) dermatomyositis (DM), (iv) immune-mediated
necrotizing myopathy (IMNM), and (v) overlap syndromes with myositis (2, 3). Within the
spectrum of antibodies two classes have been proposed (4), designated as myositis specific
antibodies (MSAs) due to their exclusive association with IIM or as myositis-associated antibodies
(MAAs) due to their prevalence in different other connective tissue disorders. This article focuses
on an overview on so far identified specific autoantibody-antigen systems in IIM. Furthermore, we
discuss the available methods, strategies and pitfalls of autoantibody detection in IIM as well as
their diagnostic performance and clinical association.




As with many other systemic autoimmune diseases, it is unclear
so far, whether and how the observed autoantibody formation
is directly associated with the pathogenesis of disease or is just
an epiphenomenon. However, the striking association between
certain autoantibodies with a distinct clinical phenotype, their
high disease specificity and their value for stratification and
prognosis of disease suggests that they may play a role in disease
induction and propagation (5). This section describes in detail
the nature and function of so far identified IIM specific antigens.
A complete overview on so far identified antigens and the
corresponding autoantibodies in adult and in juvenile patients
with IIM is given in Table 1.
The best-known autoantigen-autoantibody system in IIM is
directed against transport ribonucleoacid (t-RNA) synthetases
and represents a specific finding in patients with so named anti-
synthetase syndrome (ASS). The targeted synthetases catalyze the
binding of a specific aminoacid to their t-RNA in the cytoplasm
of each eukaryotic cell for transportation to the ribosome and
subsequent protein synthesis. At least eight t-RNA synthetases
have been identified as autoantigens. Anti-Jo1 antibodies are
the most common ones and received their designation after the
initials of the index patients (44). It is unclear, why not all t-
RNA synthetases are targeted by the immune system in ASS,
but only the tRNA synthetase for threonyl (PL-7), alanyl (PL-
12), isoleucyl (OJ), glycyl (EJ), asparaginyl (KS), phenylalanyl
(Zo), tyrosil (Ha), and finally the histidyl synthetase (Jo-1). Even
more of interest is the question, whether the antibodies can
interfere with the function of the respective t-RNA synthetase as
it has been shown for anti-Jo1 antibodies by in-vitro experiments
(45, 46). This particular antibody specificity belongsmainly to the
IgG1 isotype and binds to common epitopes (47).
For the anti-Jo1 antibodies, it was shown that the formation
of the major autoepitope is strongly dependent on proper
folding of the molecule (46). As a shared risk factor for anti–
Jo-1 autoantibody positivity, the HLA–DRB1∗0301 allele was
identified in European as well as African Americans (48). In the
Japanese population, HLA–DRB1∗0405 was associated with the
formation of an anti-tRNA antibody response (49).
Another specific antigen is the transcription intermediary
factor-1 gamma (TIF-1γ). This multi-functional protein with a
molecular weight (MW) of 140/155 kilo-Dalton (kDa) is mainly
involved in gene transcription (27, 50–53). The TIF-1 family is
composed of tripartite motif-containing (TRIM) proteins, which
are all implicated in cell proliferation, development, apoptosis,
and innate immunity (54). All TIF1 proteins share a C-terminal
chromatin reading unit consisting of a plant homeodomain
finger and a bromo-domain (BROMO) that is highly conserved
among TIF1 family members, but which is not present in any
of the other TRIM proteins (55, 56). Of note, while the most
common target in anti-TIF1-positive CAM (cancer-associated
myositis) is TIF1γ, other proteins of the TIF1 family (TIF1α
and β) may also be simultaneously targeted by the immune
system (53).
The tripartite containing motif (TRIM) allows these proteins
also to function as E3-ligases in the ubiquitination pathway to
control protein degradation, localization, and function. In this
context, it is interesting to mention that TIF1-γ is involved in
the regulation of TGF-β signaling via mono-ubiquitination of
SMAD-4 leading to suppression of TGF- β. Thus, by stimulating
cell growth and differentiation, TIF1-γ could play a pivotal
role in promoting or suppressing malignant cell growth and
differentiation (57). The known association of anti-TIF1-γ
antibodies with a high risk of cancer development in DM suggest
that this link could be not random. Of note, anti-TIF antibodies
were only rarely detectable in patients with solid cancer (3.1%) or
paraneoplastic rheumatic syndrome (3.3%) without DM (58).
Recently, it was recognized that tumors from paraneoplastic
anti-TIF1-γ positive patients showed an increased number of
genetic alterations, such as mutations and loss of heterozygosity
(LOH) in TIF1 genes (59). Compared with type-matched control
tumors from non-myositis patients, TIF1-γ staining was also
significantly more intense in tumors as well as muscle tissue
from anti-TIF1-γ positive patients. This finding could indicate
that the co-occurrence of mutations in peptide regions of TIF1
with high affinity for HLA class I and tumors with high-level
TIF1 protein expression may initiate a strong adaptive immune
response against neoplastic cells with the mutation. Interestingly,
LOH is the most frequent way to lose a mutant allele in human
cancer and this is key to tumor immune-editing, since tumor cells
with mutations producing a neo-antigen may be eliminated by
the immune system and replaced by tumor cells with LOH in
that region (without the antigenic mutation) (60, 61). Thus, these
modifications can induce an immune response, but also cause an
escape of the tumor cell from clearance.
It has been described that DM disease increases toward
the equator and strongly associate with latitude. Recently,
this observation was confirmed by another study showing
that relative prevalence of DM and frequency of anti-TIF1-
γ autoantibodies were found to be significantly negatively
associated with latitude in adult myositis. Furthermore, HLA
alleles HLA-DRB1∗ 07:01 and HLA-DQB1∗02 were strongly
associated with the DM-specific autoantibodies anti-Mi-2 as well
as anti-TIF1-γ (62).
The component of the nucleosome remodeling deacetylase
complex, Mi-2, is an autoantigen of 240 kDa MW and exists
in two isoforms Mi-2α (CHD3) and Mi-2β (CHD4). Mi-2 is
responsible for the remodeling of chromatin by de-acetylating
histones and plays a role as transcription repressor (63). The
role of anti-Mi-2 autoantibodies in the pathogenesis of DM
is unclear. However, the autoantigen Mi-2 is found to be up-
regulated in the muscle tissue of DM patients. Of note, exposure
of keratinocytes to UV radiation has been shown to increase
the expression of Mi-2 protein supporting the hypothesis that
UV radiation may be associated with the induction of anti-
Mi-2 autoantibodies (64). However, a reported increase in the
presence of anti-Mi-2 autoantibodies toward the equator was
not confirmed by a current study (62, 65). A preferential
expression was described in the nucleus of myofibers within
fascicles affected by perifascicular atrophy, particularly in the
centralized nuclei of small perifascicular muscle fibers expressing
Frontiers in Neurology | www.frontiersin.org 2 May 2019 | Volume 10 | Article 438










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Frontiers in Neurology | www.frontiersin.org 3 May 2019 | Volume 10 | Article 438










































































































































































































































































































































































































































































































































































































































































































































































































































markers of regeneration (66). In a mouse model of muscle injury
and repair, Mi-2 levels were dramatically and persistently up-
regulated duringmuscle regeneration in-vivo. Of note, premature
silencing of Mi-2 with RNA interference in vitro resulted in
accelerated myoblast differentiation. In summary, these results
indicate that this protein may play a role in modulating the
kinetics of myoblast differentiation. European and American
anti–Mi-2 antibody positive DM patients have a common genetic
risk factor DRB1∗0701 (67). Furthermore, HLA-DRB1∗0302 was
identified to be associated with anti–Mi-2 autoantibody positive
African American patients (48). Of note, all HLA molecules
were found to share a 4–amino-acid sequence motif, which was
predicted by comparative homology analyses to have identical
3-dimensional orientations within the peptide-binding groove.
The target antigen of antibodies against small ubiquitin-like
modifier activating enzyme (SAE1/2) is the SUMO-1 activating
enzyme heterodimer with a MW of 40 and 90 kDa, respectively.
This antigen is involved in the posttranslational modification
of proteins, the so called “sumoylation” (68, 69). Of note, a
strong association with the HLA-DRB1∗04-DQA1∗03-DQB1∗03
haplotype has been reported (25). This is another example in IIM,
where the association between genotype, serotype and clinical
picture suggest a link to the pathogenesis of disease.
Immune reactivity against the signal recognizing protein
hetero-complex (SRP) is associated with immune-mediated
necrotizing myopathy (IMNM). This 72/52 kDa antigen is
expressed in the cytoplasm and responsible for transport proteins
to the endoplasmic reticulum. SRP consists of six polypeptides
(including SRP19 and MIM 182175) as well as seven SL-RNA
molecules with partial homology to Alu-DNA (70, 71). Although
antibodies against SRP can target each of the different SRP
components, a signal peptide-binding 54 kDa subunit (SRP54)
represents a major epitope recognized by almost every sera
and is, therefore, preferentially used in immunoassays (72–76).
Although it is not clear, how the antibodies can interact with
the SRP1/2 autoantigen, it was shown that anti-SRP antibodies
can inhibit the translocation of secretory proteins into the
endoplasmic reticulum in-vitro and that a passive transfer of
IgG from anti-SRP+ patients with IMNM provoked muscle
deficiency through a complement-mediated mechanism in mice
model. Interestingly, also active immunization with SRP was
able to induce an immune response and provoked disease
(76, 77). A correlation between anti-SRP54 antibody titers and
disease activity was also shown in a longitudinal follow-up study
suggesting a pathogenic role of this antibody entity (78). As a
genetic risk factor, HLA- DQA1∗0102 was identified in anti–SRP
autoantibody positive African American patients (48).
The melanoma differentiation antigen 5 (MDA-5, synonym
CADM-140) with a MW of 140 kDa belongs to the family
of RIG-I-like receptors of adhesion molecules and represents
a resistance factor against double stranded RNA viruses (49,
79). The MDA-5 molecule plays an important role in the
regulation of the immune response by the innate system. In
this context, it was shown that MDA-5 bind virus particles,
e.g., picornaviruses such as coxsackievirus, and induce an
antiviral responses by producing type-I interferons and tumor
necrosis factor (80). It was also reported that hyperferritinemia
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could be a marker for rapidly progressive ILD in anti–MDA-
5 antibody positive DM patients (81, 82). In this context
many cytokines regulate the ferritin synthesis, including IL-1β,
IL-18, TNF, IFN-γ, and IL-6 and several of these cytokines
are considered to be involved in IIM pathogenesis. HLA–
DRB1∗0101/∗0405 was found to be associated with susceptibility
to anti–MDA-5 antibody positive DM in the Japanese population
(49). Interestingly the same alleles are well-known to play a role
in the susceptibility to autoantibody induction in rheumatoid
arthritis (83).
Autoantibodies against the nuclear protein 2 (NXP-2),
also known as MJ or p140 antibodies, are directed against a
nuclear matrix protein complex named NXP2/MORC3, which
is involved in regulation of p53-induced cell senescence in
the context of oncogenic signals (23). NXP-2 is associated
with the small ubiquitin modifier SUMO-2 and represses its
expression (84).
The enzyme 3-hydroxy-3-methylglutaryl-CoA reductase
(HMGCR) was recently identified as a target of autoantibodies
induced under treatment with statins. The antigen is expressed
in the ER membrane and has a MW of 200/100 kDa. HMGCR
catalyzes the conversion of HMG-CoA to mevalonic acid, which
is an important step in cholesterol biosynthesis. So far, reports
about HMGCR in myositis are rare, however in animal studies
it was demonstrated that loss of HMGCR function disrupts
vascular stability during developmental processes (4).
DIAGNOSTIC TESTING FOR
AUTOANTIBODIES IN IIM
To assess disease activity and as indicators for muscle injury in
IIM, basic laboratory diagnostics are used, such as measurements
of levels of inflammatory markers as well as serum activity and/or
concentration of muscle specific proteins including creatine
phosphokinase (CPK) or myoglobin. However, these markers are
unspecific and not helpful to distinguish between the different
forms of inflammatory muscle damage. In contrast, the reactivity
of the described autoantibodies does not sufficiently correlate
with disease activity in IIM, but can rather serve for stratification
of the disease process and outcome (85). This section focuses
on helpful information with respect to routine procedures
of autoantibody detection and the recommended diagnostic
approaches, since it is of enormous importance to know these
basics for appropriate interpretation of results.
Serum is usually used for the detection of autoantibodies, and
test procedures are performed according to the manufacturer’s
validation. From a preanalytical point of view, time point
of venepuncture and fasting status of the patient are not
relevant. However, hemolytic, lipemic or contaminated blood
samples should not be used, since the released proteins and
proteinases can interfere with the immunologic method of
detection. Especially in case of a prolonged transportation of
the blood sample, serum should be separated in advance by
centrifugation at 1,300 g. Subsequently, the serum samples can
be stored at 2–8◦C for up-to 2 weeks before analysis. A longer
period requires freezing at minus 20◦C, which presumably
allows conservation of the autoantibody reactivity for years
(86, 87). Furthermore, some treatment procedures including
administration of strong immunosuppressive drugs such as B-
cell directed therapies as well as plasmapheresis or administration
of intravenous immunoglobulins can influence the result of
detection by decreasing the concentration of the autoantibodies.
From the methodical point of few, detection of autoantibodies
in IIM is not well-standardized and no international reference
samples are available so far. In general, immunoprecipitation of
radio-labeled proteins or RNA molecules is still considered to
represent the “gold standard” (68). However, due to the time-
consuming procedure, high amount of required antigens and low
sensitivity, this method is not a routine procedure inmost clinical
laboratories. Therefore, for the detection of IIM specific and/or
associated autoantibodies several, more efficient approaches
such as immunofluorescence, ELISA and western blotting
are widely used (88–90). In general, immunofluorescence
requires large experience to interpret patterns and may not be
sensitive enough to detect all MSAs/MAA. On the other hand,
ELISA methods using recombinant antigens or immunoblotting
with denaturated antigens can probably not detect antibodies
to certain conformational epitopes. Line-blot assays allow a
qualitative detection of many antibodies in one run. In contrast,
and in accordance to the manufacturer specification only a
limited number of MSAs/MAAs can be detected by commercial
available ELISAs so far.
Indirect immunofluorescence (IIF) on HEp-2 cells, a human
epithelioma cell line, is commonly be used for detection of
anti-nuclear antibodies (ANA), but also enables detection of
antibodies against cytoplasmatic antigens. This method allows
a screening for a wide range of autoantibodies especially in
connective tissue disorders by describing the staining pattern
(e.g., nuclear, nucleolar, cytoplamatic), as well as the reactivity
titer starting with a serum dilution of usually 1:80. Although
no agreement has still been reached on the interpretation and
reporting of the ANA titres, results can be considered as weak
positive in antibody titer of ≥1:160 and as strong positive in a
titres of ≥1:640. In this context, it is important to mention that
measured titers often do not correspond with the significance
of the results. In other words, a low reactivity should not be
considered as irrelevant. Furthermore, it is also important to
pay attention to the described pattern of immunofluorescence
in the nucleus, but also the cytoplasm. It is helpful to know
that IIF on HEp-2 cells shows characteristic patterns of some
MSA or MAA antibodies such as those against PM/Scl with
prominent homogeneous staining of the nucleous, U1-RNP
with coarse speckled staining of the nucleus, Jo-1 or SRP with
fine speckled stainings of the cytoplasm (Figure 1), but is not
sufficiently accurate to be used as the only screening tool for
myositis antibodies.
Although most of the targeted antigens in IMM are expressed
within HEp-2 cells, their detection by IIF is clearly limited. The
reasons for frequent false negative results is diverse including
e.g., low expression level of the antigen or low affinity of the
antibodies causing a weak staining signal. Furthermore, the
intracellular distribution of relevant antigens in IIM is usually
diffuse generating an unspecific staining pattern. Thus, week
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FIGURE 1 | Indirect immunofluorescence with typical nuclear patterns of MSA and MAA. Immunofluorescence patterns are indicated with the terminology of the
International Consensus on ANA Patterns (ICAP).
positive results are often not recognized, as it frequently occurs
even with anti-tRNA synthetase antibodies. Nevertheless, IIF
on HEp-2 cells is an important diagnostic procedure. Table 1
summarizes frequent staining patterns in conjunction with the
respective antibody and, Figures 1, 2 show representative IIF
staining patterns indicating the respective nomenclature for the
most frequent MSAs and MAAs by International Consensus on
Autoantibody Patterns (ICAP).
For the detection of classical and new myositis antibodies,
multi-analyte line blot assays and ELISA are the current routine
methods of choice. In contrast to IIF, commercial ELISAs and
line-blot assays use purified or recombinant expressed antigens
for detection of antibodies. These methods allow the targeted
detection or confirmation of respective antibodies in serum
samples, which are usually diluted 1:100. In contrast to semi-
quantitative results provided by line-blot assays (with negative,
weak or strong positive signals, see Figure 3), ELISA based
methods allow a better quantification of antibody reactivity,
especially if international standards will be available. However,
the majority of ELISA methods published hitherto to detect
novel myositis antibodies are in-house made and most of the
commercial ELISAs only report negative or positive results by
using a cut-off level of reactivity defined by the providing
manufacturer. A multiplex-approach for detection of several
antibodies in one immunoassay has also limitations and pitfalls
due to the difficult optimization of the cut-off for all investigated
antibodies. Therefore, it is always important to check the
plausibility of the obtained results, not only in cases of weak
or borderline reactivity, but also in case of discordance between
the different immunoassays (e.g., negative ANA staining pattern
but positive anti-PM/Scl antibodies in ELISA or line-asays).
On the solid phase of an immunoassay, the antigen structure
can be altered yielding a false positive antibody reactivity,
which is not directed against the native antigen. Therefore,
it is important, that involved diagnostic laboratories are be
informed about the clinical suspected diagnosis and provide
high quality assays proven by regular internal and external
quality controls.
The major advantage of ELISA and line blot test
assays is the option of automation test fastness. In this
context, the development of commercial quantitative
immunoassays including ELISA, chemiluminescence
and immunofluorometry has facilitated the use at large
scale in routine laboratories and provided interesting
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FIGURE 2 | Indirect immunofluorescence with typical cytoplasmic patterns of MSA and MAA. Immunofluorescence patterns are indicated with the terminology of the
International Consensus on ANA Patterns (ICAP). AC-19-cytoplasmic dense fine speckled, AC-20-cytoplasmic fine speckled.
FIGURE 3 | Detection of anti-Jo-1 and anti Ro-52 antibody reactivity in a line-blot assay showing the reaction intensity by a scan-software of the fabricant
(EUROLINE, Euroimmune, Germany).
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information on correlation of clinical and serological findings
in IIM.
CORRELATION OF MSA WITH CLINICAL
FINDINGS
In addition to inflammatory lesions of skeletal muscles,
involvement of other organs such as skin, joint, lung and
heart is frequent in IIM. Extra-muscular involvement, especially
interstitial lung disease (ILD) and underlying malignancy in
cancer-associated myositis (CAM) are the two dominating
factors contributing to increased mortality in IIM-patients (91,
92). This section gives an overview on the association of MSA
with clinical findings and their diagnostic performance. The
incidence of most of the so far identified autoantibody activities
of European patients is in agreement with similar studies of
Japanese and American patients (7).
ANTIBODIES AGAINST T-RNA
SYNTHETASES
Patients with antibodies against t-RNA synthetases are prone
to develop the so called anti-synthetase syndrome (ASS)
characterized by myopathy, interstitial lung disease (ILD), non-
erosive arthritis, fever, Raynaud’s phenomenon and mechanic’s
hands. Since not all symptoms are present at disease onset,
ASS should be carefully considered in patients presenting with
isolated arthritis, even in those with erosive manifestation
and RF as well as ACPA-positivity (93, 94). The presence of
anti-synthetase antibodies can be suspected if a characteristic
cytoplasmic pattern on HEp2 cells is evident (Figure 1).
However, confirmation is needed using ELISA, immunoblot
or line-assays with the isolated antigens. Depending on the
diagnostic method anti-Jo-1 antibodies are the most frequent
autoantibodies in IIM, they can be detected in 20–30% of patients
(7, 95). Titers of Jo-1 antibodies were shown to correlate with
disease activity in adults (95). In muscle biopsies of anti-Jo-
1 positive myositis patients a specific histologic pattern with
peri-fascicular necrosis has been described (96).
The CT- and histomorphologic pattern of ILD in anti-
synthetase syndrome can vary between non-specific interstitial
and organizing pneumonia (97). Antibodies against PL-7 and
PL-12 are positive in up to 5% of IIM patients. Clinically they
are associated with less muscle involvement but with a higher
proportion of ILD, which might have an acute onset (98).
Furthermore, pericarditis was observed in up to 50% of anti-PL7
positive patients (99). Antibodies against OJ, EJ, KS, Zo, and Ha
are rare and only present in 1–3% of patients with ARS. The
coincidence of anti-Ro52/TRIM21with anti-ASS antibodies was
described to be associated with severe myositis and arthropathy
as well as with an increased risk of cancer (7, 99, 100). The
onset of ILD and myositis, as leading symptoms in ASS, can be
subsequently or in parallel, while the course of ILD must not
necessarily be progressive.
DM-Specific Antibodies
Anti-Mi-2 antibodies have a high specificity for both adult and
juvenile DM (JDM). Mi-2-antibodies produce a fine speckled
nuclear pattern in IIF on HEp-2 cells (AC-4 of the ICAP
nomenclature) and are detectable in approximately 30% in
adult and 10% in juvenile DM (JDM) patients, respectively.
Patients with positive anti-Mi-2 antibodies have usually a milder
myopathy, lower risk of interstitial lung disease (ILD) and
malignancy (101). Skin manifestations, such as Gottron’s sign
and heliotrope rash, as well, rashes in neck (V rash) and
upperback (shawl rash) or cuticular overgrowth are typical.
Patients respond well to steroid therapy and have a good
prognosis. Furthermore, levels of Mi-2 antibodies were shown
to correlate with clinical response to B-cell depletion therapy
(102). Although DM with antibodies against Mi2-β can be
associated with neoplasia (e.g., colon or mama-carcinoma), anti-
Mi-2 antibodies are in general associated with a lower risk
of paraneoplastic myositis and hence considered to be a good
prognostic factor.
Anti-TIF1γ (anti-155/140) antibodies are detectable in 13–
21% of patients with tumor associated adult DM and in
approximately 30% of severe juvenile DM patients (23, 27). In
fact, these antibodies are the most frequent marker in juvenile
IIM (JIIM) and are primarily associated with JDM. They were
originally found almost exclusively in JDM, in about of 23–
29% of cases using immunoprecipitation and immunoblotting.
Interestingly, in recent studies including a total of 374 cases
with JIIM, 131 cases (35%) were found to be positive for these
antibodies. In detail, the antibodies were detectable in 38%
of patients with JDM (123/320) and in 26% of patients with
an overlap syndrome with myositis (8/31) (103, 104). TIF-γ-
antibodies are known to be very frequently associated with
malignancy in adults with a specificity of 89%, sensitivity of
78%, and positive and negative predictive values of 58 and
95%, respectively (105). In contrast to adults, there is no
paraneoplastic association in JIIM (106). Skin manifestations are
characterized by a usually slowly progressive onset, but are more
extensive than in other JDM groups. In fact, skin ulcerations and
lipodystrophy were reported to be particularly associated with
these antibodies. However, this was not reported uniformly, since
recent studies did not observe ulceration or V-rashes significantly
more frequent in this group than in others (104). Of note, it
has been shown that levels of TIF-γ-antibodies correlate with
response to B-cell depletion therapy in pediatric patients (102).
Anti-NXP2 antibodies (MJ or p140) cause a fine speckled
ANA pattern on IIF, but this pattern is often misinterpreted
as variable nuclear dots (Figure 1). These antibodies have
been originally described in children with JDM in about 25%
of cases (107, 108). In a cohort of 436 patients with JIIM,
their prevalence was reported to be approximately 21% in
JDM, 9% in JPM and 15% in overlap syndromes (juvenile
connective tissue myositis, JCTM) (104). Subsequently, anti-
NXP2 antibodies have been also detected in approximately
30% of patients with DM and 8% with PM in a cohort of
58 adult Italian patients (109), but in only 1.6% of 507 adult
Japanese patients (110). In the Italian cohort, a good response to
therapy was reported for muscle involvement (109). In juvenile
Frontiers in Neurology | www.frontiersin.org 8 May 2019 | Volume 10 | Article 438
Stuhlmüller et al. Autoantibodies in Idiopathic Inflammatory Myopathies
FIGURE 4 | MDA5 positive patient with an amyopathic dermatomyositis (A) maculopapular palmar rash and hyperkeratosis, (B) rapid progression of ILD
manifestations within 5 weeks.
DM, the autoantibodies directed against NXP-2 are frequently
associated with calcinosis and ischemic muscle involvement in
up to 60% of cases (111). In adults, a possible association
was reported with malignancies such as mamma-, uterus- and
pancreas-carcinomas.
The ANA pattern of anti-MDA5 antibodies on HEp-2 cells in
IIF is usually negative. These antibodies were identified for the
first time in East-Asian populations. They are more frequently
observed in adult DM and were reported in a prevalence of 19–
35% (19, 81). In a study with 285 patients with JDM (112), anti-
MDA5 antibodies were detectable in 7.4% of patients (21/285)
and a recent review reports a prevalence of 0–13% in Europe
and USA (113). The typical clinical manifestations of adult IIM
patients with anti-MDA5 antibodies were amyopathic myositis
with rapidly progressive interstitial lung disease (ILD), which
in turn determines a high mortality rate in these patients
(Figure 4). However, ILD must not be rapidly progressive in
every case. In contrast to Asian patients, Caucasian patients often
show skin ulcerations and painful palmar papules (114, 115).
Furthermore, differences were also reported for Asian compared
to Caucasian JDM associated with MDA-5 antibodies. In this
context, Japanese patients showed a pulmonary involvement in
nearly 50% of patients, whereas the incidence of ILD was much
lower in Caucasians. JDM patients with anti-MDA5 antibodies
show frequent skin as well as oral ulceration, but no calcinosis
and had less severe muscle weakness compared other JDM
subtypes. Of note, ILD was found in 4 of 12 cases (19%) on
chest X-ray. None of these anti-MDA5 antibodies positive ILD
patients was positive for anti-synthetase antibodies suggesting
that anti-MDA5 antibodies represent an own subtype of IIM.
This study also revealed that more patients with anti-MDA5-
antibodies were in remission after 2 years compared to patients
without these antibodies. In the follow-up, patients in remission
showed a decline in the titer of MDA5 antibodies. These results
resemble those of prior studies in which antibodies were shown
to disappear during disease remission (20).
The anti-SAE-antibodies were originally described in
adults with DM exhibiting an amyopathic onset with skin
manifestations, but who may develop myositis several months
later. Lung involvement was infrequent reported. The antibodies
were detected in approximately 7–8% of adult Caucasian patients
with DM (25, 116). In a study with 110 Japanese patients with
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DM including 13 with JDM, only 2 patients with DM (1,8%)
were shown to have SAE-antibodies (117). In a large study with
436 patients with JIIM, only one patient with JDM was positive
for anti-SAE-antibodies (118). Therefore, the presence of
SAE-antibodies in patients with JIIM seems to be extremely rare.
Immune Mediated Necrotizing Myositis
(IMNM)
Anti-SRP-Antibodies were detected in about 3 to 7% of
adults with IIM (73, 119). In JIIM, these antibodies are
even more infrequently observed in only 1.6% of patients
exclusively with juvenile polymyositis (JPM) (103, 120). The
presence of SRP-antibodies can be suspected by detection
of a cytoplasmic staining pattern in ANA IIF (Figure 1).
Adults with anti-SRP-antibodies develop typically an acute
necrotizing myopathy with prominent muscle impairment
without skin manifestations. Compared to other myositis forms,
a satisfactory response to medicament treatment is difficult to
achieve. Pulmonary involvement, Raynaud-symptoms, arthritis
or overlap syndromes are infrequent. Similar to adults, juvenile
patients have very high levels of CPK as well as often cardiac
involvement detectable e.g., by ECG or echocardiography.
Of note, adult patients show frequently Raynaud-symptoms,
dysphonia and dyspnea under exertion (107). Compared to
other forms of JIIM, onset of symptoms is late in patients
with anti-SRP-antibodies. However, two unusual cases have
been published recently with onset in the first decade of life
showing muscular dystrophy and a low degree of inflammation
in muscle biopsy (107). The antibody titer against SRP seems
to correlate with clinical activity as well as with levels of CPK
in adults as well as in JIMM and can be used for monitoring of
therapy (78, 121).
Antibodies against the enzyme 3-hydroxy-3-methylglutaryl-
CoA reductase (HMGCR) have been identified initially in
patients with immune mediated necrotizing myositis (IMNM) in
association with statin treatment. Overall, autoantibodies against
HMGCR are detectable in 6–7% of patients with IIM (28–
30). Myalgias, as a common side effects under statins, are not
associated with this form of myositis and positive HMGCR-
antibodies. In fact, only a minority of patients under statin
treatment develops myopathy with anti-HMGCR-antibodies
(122). Furthermore, even patients without statin treatment
can develop necrotizing myositis with positive anti-HMGCR-
antibodies (123). Results of a multicenter study show that
the majority of patients with anti-HMGCR antibodies have
IMNM. In this study, the prevalence of anti-HMGCR antibodies
in different subpopulations of IMNM exposed to statins was
approximately 70%, and even 75% in patients above the age of
50 years. However, approximately 45% of INMN patients had
no exposure to statins and in 5% of cases did not show muscle
necrosis (124). In contrast to non-immune statin myopathy,
which resolves after stopping statin therapy, patients with anti-
HMGCR antibodies have a persistent autoimmune response
despite cancelation of treatment with the inducing agent. Similar
to SRP antibodies, the titer of anti-HMGCR antibodies correlates
with the clinical activity of necrotizing myositis. However, in
contrast to SRP antibodies it is not known, whether antibody
titres can normalize under effective therapy (125–127). Of note,
these antibodies have also been detected in children after statin
therapy recently, however, the experience with these cases is
very limited (128, 129).
The detection of anti-HMGCR antibodies was performed by
only few laboratories using immunoprecipitation so far, since no
standardized commercial assay was available. An introduction
of other methods such as ELISA or chemiluminescence for the
detection of anti-HMGCR antibodies could make this test widely
available to facilitate the diagnostic possibilities (130). However,
since such immunoassays can yield false positive results due to
detection of low avidity antibodies, a confirmatory analysis by
immunoprecipitation can be recommended (131). Interestingly,
usage of rat hepatocytes in indirect immunofluorescence was
proposed (132). However, although some laboratories have
adopted this strategy, there are not yet available data from an
extended use of this approach (133). Of note, in a French cohort
study HMGCR positive IMNM-patients were found to be at
higher risk for malignancy (134).
AUTOANTIBODIES IN DM AND THE RISK
OF CANCER
A high risk of cancer development is well-described and has led
to the sub-categorization of cancer associated myositis (CAM)
(135). The overall risk of cancer in myositis is significantly higher
than in the age-matched population and approximately 10% of
IIM are associated with malignancies (134–138). In DM, the
risk is especially increased in the first 5 years after diagnosis
(139–144). The most common cancers among the reported
cases associated with DM are nasopharyngeal carcinoma and
adenocarcinoma of the ovary, lung, pancreas, stomach and colon
(139–145). Many studies have claimed the presence or absence of
certain antibodies as markers for the risk of cancer in myositis.
The autoantibody profile is considered a useful tool to identify
patients at risk for CAM (32). In this context, the best established
antibodies are directed against TIF1-γ with a high sensitivity and
specificity for cancer associated DM in adult patients (27, 52, 53,
105, 146, 147), but not in JDM (50). Furthermore, also NXP-2
positivity in DM patients has been identified as a risk factor for
malignancy (148). The association of anti-synthetase and anti-
HMGCR antibodies with cancer is less clear and needs further
confirmation. To exclude an associated malignancy in clinical
practice repetitive examinations can be recommended in DM
patients at risk, whereas clear guidelines on the frequency and
extension of such diagnostic procedures are missing so far.
SUMMARY
Autoantibodies in IIM are very important diagnostic and
prognostic markers, which can help to facilitate our approach
to these rare and divers diseases. They correlate closely with
the clinical manifestation of disease and allow stratification of
patients. However, a laboratory result provides always only a
piece of the diagnostic puzzle and should always be questioned
if not plausible. For this purpose, a better knowledge on the
Frontiers in Neurology | www.frontiersin.org 10 May 2019 | Volume 10 | Article 438
Stuhlmüller et al. Autoantibodies in Idiopathic Inflammatory Myopathies
limitations of the laboratory procedures is necessary and tests
should only be performed if indicated according to the clinical
picture. To allow comparison and improve reproducibility, the
existing assays require uniform standards on an international
level, and optimized methods for a broader distribution. If
these issues can be solved, antibodies in IIM will play a
more prominent role in the classification of disease. Another
interesting and important tasks for the future will be to
investigate the treatment response in IIM patients according
to their antibody profile in more detail. This includes the
question, whether different antibodies correlate with disease
activity, but can be also used for an individualized approach
to predict the response and outcome. Finally, the interaction of
the antibodies with the targeted antigens is of major interest
especially for the IIM specific entities. A deeper understanding
on the mechanisms behind the induction of the respective
immune response as well as on the potential role of the targeted
antigens in IIM can improve our insight into the pathogenesis
of disease.
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